Skip to main content
SpringerLink
Log in

ASH 2013: short review on myeloproliferative neoplasms

  • short review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Abstract

At the 2013 annual meeting of the American Society of Hematology, the role of calreticulin in essential thrombocythemia and primary myelofibrosis as well as safety aspects in second-generation tyrosin kinase inhibitor treatment of chronic myeloid leukemia have been major issues in the field of myeloproliferative neoplasms.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.

    Article  PubMed  CAS  Google Scholar 

  2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  3. Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014;123(24):3714–9.

    Article  PubMed  CAS  Google Scholar 

  4. Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood. 2014;123(14):2220–8.

    Article  PubMed  CAS  Google Scholar 

  5. Tefferi A, Wassie EA, Guglielmelli P, Gangat N, Belachew AA, Lasho TL, et al. Type 1 versus type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients. Am J Hematol. 2014 Aug;89(8):E121-4. doi: 10.1002/ajh.23743.

  6. Vannucchi AM, Rotunno G, Bartalucci N, Raugei G, Carrai V, Balliu M, et al. Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value. Leukemia. 2014. doi:10.1038/leu.2014.100.

  7. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123(10):1552–5.

    PubMed  CAS  Google Scholar 

  8. Saglio G, Hochhaus A, Hughes TP, Clark RE, Nakamae H, Kim D-W, et al. ENESTnd update: nilotinib (NIL) vs imatinib (IM) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) and the impact of early molecular response (EMR) and sokal risk at diagnosis on long-term outcomes. Blood. 2014;122(21); abstract #92.

  9. Cortes JE, Hochhaus A, Kim D-W, Shah NP, Mayer J, Rowlings P, et al. Four-year (Yr) follow-up of patients (Pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib or imatinib: efficacy based on early response. Blood. 2014;122(21); abstract #653.

  10. Aichberger KJ, Herndlhofer S, Schernthaner GH, Schillinger M, Mitterbauer-Hohendanner G, Sillaber C, et al. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML. Am J Hematol. 2011;86(7):533–9.

    Article  PubMed  CAS  Google Scholar 

  11. Hadzijusufovic E, Albrecht-Schgoer K, Huber K, Grebien F, Eisenwort G, Schgoer W, et al. Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells: a potential explanation for drug-induced vasculopathy in CML. Blood. 2014;122(21); abstract #257.

  12. le Coutre P, Hughes TP, Mahon F-X, Kim D-W, Steegmann JL, Shah NP, et al. Peripheral arterial occlusive disease (PAOD) in patients (Pts) receiving dasatinib: experience across multiple clinical trials. Blood. 2014;122(21); abstract #1489.

  13. Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125(17):2128–37.

    Article  PubMed  CAS  Google Scholar 

  14. Cortes JE, Kim D-W, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, et al. Ponatinib in patients (pts) with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) resistant or intolerant to dasatinib or nilotinib, or with the T315I BCR-ABL mutation: 2-year follow-up of the PACE trial. Blood. 2014;122(21); abstract #650.

  15. Brümmendorf TH, Cortes JE, Khoury HJ, Kantarjian HM, Kim D-W, Conlan MG, et al. Bosutinib as therapy for chronic phase chronic myeloid leukemia following resistance or intolerance to imatinib: 48-month update. Blood. 2014;122(21); abstract #2723.

  16. Cortes JE, Kantarjian HM, Khoury HJ, Brümmendorf TH, Conlan MG, Wang K, et al. Long-term evaluation of vascular toxicity in patients with Ph + leukemias treated with bosutinib. J Clin Oncol. 2014;32(15); abstract #7060.

Download references

Author information

Authors and Affiliations

  1. Universitätsklinik für Innere Medizin V, Hämatologie und Onkologie, Medizinische Universität Innsbruck, Anichstr. 35, 6020, Innsbruck, Austria

    Stefan Schmidt MD

Authors
  1. Stefan Schmidt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefan Schmidt MD.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schmidt, S. ASH 2013: short review on myeloproliferative neoplasms. memo 7, 138–140 (2014). https://doi.org/10.1007/s12254-014-0168-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-014-0168-2

Keywords

Search

Navigation